✦ LIBER ✦

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients

✍ Scribed by M. M. Uttenreuther-Fischer; C. S. Huang; A. L. Yu

Book ID: 105229905
Publisher: Springer-Verlag
Year: 1995
Tongue: English
Weight: 834 KB
Volume: 41
Category: Article
ISSN: 0340-7004
DOI: 10.1007/bf01526552

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ocular symptoms in children treated with

Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma

✍ Bernhard Kremens, Barbara Hero, Joachim Esser, Peter Weinel, Judith Filger-Brill 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 68 KB

Pharmacokinetics of anti-ganglioside GD2

Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients

✍ Martina M. Uttenreuther-Fischer; Chuin-Sheng Huang; Ralph A. Reisfeld; Alice L. 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 823 KB

Phase I Trial of a Novel Anti-GD2 Monocl

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

✍ Navid, F.; Sondel, P. M.; Barfield, R.; Shulkin, B. L.; Kaufman, R. A.; Allay, J 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 247 KB

A Phase I/IB trial of murine monoclonal

A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma : A report of the Children's Cancer Group

✍ Jami D. Frost; Jacquelyn A. Hank; Gregory H. Reaman; Sharon Frierdich; Robert C. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Phase I/IB study of the Children's Cancer Group (CCG) and were monitored for toxicities and response

Phase I trial of chimeric (human-mouse)

Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer

✍ Gary E. Goodman; Ingegerd Hellstrom; Dale E. Yelton; James L. Murray; Sarah O'Ha 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 685 KB

222 A first-in-human, phase I trial of t

222 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors

✍ D.C. Smith; P. Eisenberg; R. Stagg; G. Manikhas; A. Pavlovskiy; B. Sikic; A. Kap 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB